Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to Strong-Buy at Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

SUPN has been the subject of a number of other reports. Stifel Nicolaus boosted their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research report on Wednesday. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Finally, Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $54.73 on Friday. Supernus Pharmaceuticals has a 12 month low of $29.16 and a 12 month high of $59.68. The stock has a fifty day moving average price of $50.69 and a 200 day moving average price of $48.30. The company has a market cap of $3.14 billion, a P/E ratio of -80.48, a PEG ratio of 1.73 and a beta of 0.71.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the sale, the senior vice president owned 15,496 shares in the company, valued at $781,153.36. This represents a 56.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the transaction, the vice president owned 14,508 shares in the company, valued at approximately $644,735.52. This represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 25,185 shares of company stock valued at $1,268,022. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SUPN. Sit Investment Associates Inc. increased its position in Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after purchasing an additional 250 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the last quarter. Arizona State Retirement System raised its position in Supernus Pharmaceuticals by 1.7% during the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock valued at $791,000 after acquiring an additional 277 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the last quarter. Finally, Maryland State Retirement & Pension System lifted its stake in Supernus Pharmaceuticals by 3.6% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.